Respiratory season is coming, and the Union wants its shelves stocked. The European Commission has signed a joint procurement contract for an RSV vaccine, giving member states a route to up to 24 million doses of Moderna’s mRNA shot mRESVIA before the 2026-2027 winter arrives.

Respiratory syncytial virus fills hospital wards every cold season, hitting infants and older adults hardest. Health commissioner Hadja Lahbib framed the deal as a way to lift preparedness, protect the most vulnerable, and ease the strain that winter infections place on stretched health systems.

The contract runs through the Union’s Joint Procurement Agreement, a voluntary mechanism that lets countries buy medical countermeasures together and negotiate as a bloc. Thirty-nine countries have now signed that agreement, pooling their purchasing weight to secure better terms than any single state could manage alone.

Joint buying answers a lesson from recent years. When countries bid against each other for scarce supplies, prices climb and smaller states lose out. A single framework contract spreads access more evenly and gives manufacturers a clearer picture of demand across the continent. Companies can plan production runs with more certainty, which in turn steadies supply through the peak of the season.

The framework does not force any government to buy. Instead it opens a channel that health ministries can draw on as their vaccination plans require, letting each country decide how many doses to order and when to roll them out.

RSV protection has expanded fast. New vaccines and antibody treatments now target both ends of the age range, and public health agencies have started weaving them into seasonal campaigns alongside flu and Covid shots.

The Commission set out the terms in its public health update, which confirms the volume and the winter timeline.

The deal also fits a broader push on medicine security. Brussels has spent the past year tightening supply chains, listing critical medicines, and reforming pharmaceutical law to blunt the shortages that have dogged antibiotics and other essentials.

The move also signals confidence in newer vaccine platforms. Regulators cleared the first RSV shots for older adults and expectant mothers only recently, and joint procurement gives that young market the scale it needs to reach clinics quickly.

Whether the doses reach arms in time now rests with national systems. The contract secures supply; the harder task of persuading people to take the shot before the cold months bite still falls to governments and doctors across the member states.